secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-015768
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q2 net loss $35.7M; cash $277.4M; PC14586 combo with KEYTRUDA planned
--------------------------------------------------------------------------------

- Net loss for H1 2022: $35.7M vs $24.5M YoY; cash, cash equivalents and marketable securities $277.4M as of June 30, 2022.
- R&D expenses $23.3M in H1 2022 vs $15.2M in H1 2021, driven by PC14586 clinical trial costs.
- Initial PC14586 Phase 1 data presented at ASCO; entered clinical collaboration with Merck for PC14586 + KEYTRUDA combo trial starting Q4 2022.
- Appointed Marc Fellous, M.D. as VP, Clinical Development and Medical Affairs; previous experience at Bayer and Roche.
- Net cash used in operations $31.7M in H1 2022 vs $22.1M in H1 2021; cash burn increased 43%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017022015768/0000950170-22-015768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017022015768/pmvp-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer